TD-0903
Inflammatory Lung Disease (e.g., previously COVID-19)
Key Facts
About Theravance Biopharma
Theravance Biopharma is dedicated to transforming the treatment of specialty respiratory diseases through the discovery and development of 'Medicines that Make a Difference®'. The company achieved a significant milestone with the FDA approval and commercialization of YUPELRI® for COPD, which is co-commercialized with Viatris in the United States. With a strategic focus on insight, innovation, and managing uncertainty, Theravance Biopharma aims to create shareholder value by advancing its pipeline of organ-selective medicines for serious lung diseases. Its leadership team brings decades of experience from major pharmaceutical companies, guiding the company's integrated research, development, and commercial efforts.
View full company profile